Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Sodium Fusidate vs Linezolid in ABSSSI
NCT02570490Phase 3Completed
- Sponsor
- Arrevus
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of fusidic acid in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Arrevus. Started Nov 2015; status: completed.
02
Drugs
fusidic acid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02570490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570490.